UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
Report of Foreign Private Issuer
Pursuant to Rule13a-16 or15d-16
Under the Securities Exchange Act of 1934
For the month of April, 2018
Commission File Number001-38079
UROGEN PHARMA LTD.
(Translation of registrant’s name into English)
9 Ha’Ta’asiya Street
Ra’anana 4365007, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
On April 3, 2018, UroGen Pharma Ltd. issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form6-K.
| | |
Exhibit | | |
| |
| 99.1 | | Press Release, dated April 3, 2018: UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial ofUGN-101 (MitoGel™) forNon-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | |
| | UROGEN PHARMA LTD. |
| | |
| April 4, 2018 | | By: | | /s/ Gary S. Titus |
| | | | Gary S. Titus |
| | | | Chief Financial Officer |
